NCT03157167 2025-03-05
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Navidea Biopharmaceuticals
Phase 1 Completed
Navidea Biopharmaceuticals
Cardinal Health 414, LLC
Stanford University
Stanford University
Maimonides Medical Center
Navidea Biopharmaceuticals
Kettering Health Network
Cardinal Health 414, LLC
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals